{
    "2018-11-26": [
        [
            {
                "time": "2018-12-05",
                "original_text": "Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss",
                "features": {
                    "keywords": [
                        "Luxturna",
                        "EU Approval",
                        "Vision Loss"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-15",
                "original_text": "4 Reasons Why Lilly is Up More Than 30% This Year So Far",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Up",
                        "More Than 30%"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-20",
                "original_text": "Endocyte Stock Has Seen a Solid Hike in 2018",
                "features": {
                    "keywords": [
                        "Endocyte",
                        "Stock",
                        "Solid Hike"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-10",
                "original_text": "Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics",
                "features": {
                    "keywords": [
                        "Genentech",
                        "blood cancer",
                        "Gilead",
                        "HIV PrEP",
                        "IPO",
                        "antibiotics"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-08-25",
                "original_text": "Novartis CEO: 4 factors can help the industry price and pay for lifesaving cell and gene therapies",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "cell and gene therapies"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "European approval of Spark Therapeutics' gene therapy triggers $25M payment",
                "features": {
                    "keywords": [
                        "European approval",
                        "Spark Therapeutics",
                        "gene therapy",
                        "$25M payment"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}